Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$105.18 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.61M
Market Cap
$10.97B
Enterprise Value$13.47B
Total Cash (Recent Filing)$233.00M
Total Debt (Recent Filing)$455.10M
Price to Earnings (P/E)34.0
Beta0.56
Next Earnings
Apr 30, 2025EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding99,703,530
10 Day Avg. Volume1,255,590
30 Day Avg. Volume1,606,814
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)N/A
Price to Sales (P/S)4.66
Price to Cash Flow (P/CF)11.30
P/FCF Ratio11.30
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.80
Enterprise Value/Ebitda22.07
Forecast
1Y Price Target
$164.45Price Target Upside46.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Bulls Say, Bears Say
Bulls Say
Market PositionNeurocrine is in a strong position to increase shareholder value.
Product PerformanceNeurocrine Biosciences is expected to see potential upside with multiple commercial products like Ingrezza and Crenessity and late stage programs in schizophrenia and depression.
Sales PotentialBuy-side expectations for Crenessity's first-year sales are surpassing those of the sell-side, suggesting higher sales potential.
Bears Say
Market CompetitionAnalysts see Ingrezza cannibalizing Austedo XR market share due to effective dosing and improved payer dynamics, projecting higher peak sales.
Sales ExpectationsStreet expectations for Crenessity's first-year sales are considered aggressive.
---
Ownership Overview
1.08% Insiders
24.91% Mutual Funds
24.62% Other Institutional Investors
20.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $105.17 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $10.97B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Apr 30, 2025 which is in 37 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 06, 2025. The company reported $1 earnings per share for the quarter, missing the consensus estimate of $1.606 by -$0.606.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 0.83.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,703,530 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1 in its last earnings report, missing expectations of $1.606. Following the earnings report the stock price went down -18.53%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
---
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$164.45 (46.94% Upside)
$164.45 (46.94% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.13%
12-Months-Change
Fundamentals
Return on Equity
14.16%
Trailing 12-Months
Asset Growth
15.53%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.
---
NBIX Company Deck
---
NBIX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Neurocrine's strong performance in 2024 with record sales for INGREZZA and the successful launch of Quinicity. While there are challenges, such as increased competitive pressure and a measured launch for Quinicity, the company is taking proactive steps to address these issues. The overall sentiment is cautiously optimistic with a focus on growth and expansion in the neuroscience field.Read More>---
NBIX Stock 12 Month Forecast
Average Price Target
$164.45
▲(46.94% Upside)
Technical Analysis
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+8.70%
reiterated a buy rating 4 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +8.70% per trade.
---